HC Wainwright & Co. Maintains Buy on Microbot Medical, Lowers Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju maintains a Buy rating on Microbot Medical (MBOT) but lowers the price target from $8 to $7.
April 17, 2024 | 9:52 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Microbot Medical's price target was reduced from $8 to $7 by HC Wainwright & Co., although the Buy rating was maintained.
The adjustment in price target by HC Wainwright & Co. reflects a revised valuation outlook for Microbot Medical, though the continued Buy rating indicates a positive view on the company's fundamentals. This mixed signal could lead to neutral short-term price movement as investors weigh the lowered price target against the maintained confidence in the company's prospects.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100